Two years on, Al­ler­gan’s $1.7B NASH drug still looks weak — at best

Five months af­ter No­var­tis stepped up to col­lab­o­rate with Al­ler­gan on a com­bo NASH pro­gram, Al­ler­gan $AGN has fol­lowed up with what it de­scribes as an en­cour­ag­ing fol­lowup snap­shot to the mid-stage da­ta for their drug ceni­crivi­roc.

But that could take some ex­plain­ing.

Their drug — which flat failed the pri­ma­ry and one sec­ondary in the Phase IIb — un­sur­pris­ing­ly missed the com­pos­ite end­point look­ing at a one-stage drop in pa­tients’ dis­ease score with symp­toms sta­bi­liz­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER